Single-Cell Omics Market to Reach USD 12.05 Billion by 2034, Growing at a 16.14% CAGR | Towards Healthcare
The single-cell omics market size is calculated at USD 2.35 billion in 2025 and is expected to reach around USD 12.05 billion by 2034, growing at a CAGR of 16.14% for the forecasted period.
Ottawa, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The global single-cell omics market size was valued at USD 1.94 billion in 2024 and is predicted to hit around USD 12.05 billion by 2034, rising at a 16.14% CAGR, a study published by Towards Healthcare a sister firm of Precedence Research.
The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ https://www.towardshealthcare.com/download-sample/5561
Key Takeaways
- North America held a major share of the market in 2024.
- Asia Pacific is expected to grow at the fastest CAGR in the studied years.
- By product type, the single-cell genomics segment led the Single-Cell Omics market in 2024.
- By product type, the single-cell metabolomics segment is expected to grow notably during 2025-2034.
- By application, the oncology segment registered dominance in the market in 2024.
- By end use, the academic and research organization segment registered dominance in the market in 2024.
- By end use, the pharmaceutical and biotechnology companies segment is expected to witness rapid expansion in the coming years.
What is Single-Cell Omics?
The global single-cell omics market mainly refers to the increasing adoption of technologies that perform molecular analysis at the individual cell level, moving beyond traditional bulk analysis methods to reveal cellular heterogeneity with high precision. A key advantage driving market expansion is the unparalleled ability of single-cell technologies to identify rare cell populations, understand complex disease mechanisms in conditions like cancer and neurological disorders, and advance personalized medicine by enabling the development of highly targeted therapies.
Key Metrics and Overview
| Metric | Details | |
| Market Size in 2024 | USD 4.65 Billion | |
| Projected Market Size in 2034 | USD 9.16 Billion | |
| CAGR (2025 - 2034) | 7 | % |
| Leading Region | North America | |
| Market Segmentation | By Product, By Technology, By Application, By End-Use, By Region | |
| Top Key Players | Agilent Technologies, Beckman Coulter Lifesciences, Becton, Dickinson and Company, BioAffinity Technologies, Biotium, Bio-Rad Laboratories, Cytek Biosciences, Danaher Corporation, LabCorp Drug Development, Luminex Corporation, Sony Corporation, Sysmex Corporation, Thermo Fisher Scientific | |
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
What are the Key Drivers in the Single-Cell Omics Market?
A prominent driver is the growing prevalence of complex diseases like cancer, neurological disorders, and autoimmune conditions, and continuous innovation in single-cell analysis platforms, such as next-generation sequencing, microfluidics, and bioinformatic tools for data analysis. Increases research funding and investment, and focuses on personalized medicine and the rising demand for single-cell applications.
What are the Major Trends in the Single-Cell Omics Market?
- In June 2024, Mission Bio: Launched the Tapestri Single-cell Multiple Myeloma Multiomics Solution for simultaneous DNA and protein analysis in multiple myeloma research
- In November 2024, Scale Biosciences offers the QuantumScale Single Cell RNA Kits, providing a highly cost-efficient approach to analyze millions of cells simultaneously
- In June 2024, Bio-Rad Laboratories introduced the ddSEQ™ Single-Cell 3' RNA-Sequencing Kit for reliable gene expression analysis.
What is the Emerging Challenge in the Single-Cell Omics Market?
The market is mainly facing a hurdle in the initial development cost, and the price of specialized instruments, reagents, and consumables remains a major barrier. Technological complexity and variability, single-cell omics generate vast and complex datasets that require sophisticated bioinformatics expertise and high-performance computing, a lack of standardization and regulatory compliance.
Become a valued research partner with us - https://www.towardshealthcare.com/schedule-meeting
Regional Analysis
How did North America Dominate the Market in 2024?
In 2024, North America captured the biggest revenue share by 47% of the market. The technological advancements and the critical need to understand cellular heterogeneity in complex diseases like cancer. The trends focus on multiomics integration and AI-powered analysis tools. These innovations are transforming life sciences research and propelling the field towards the realization of precision medicine.
For instance,
- In February 2025, the BRAIN Initiative in the U.S. have allocated significant funds for research that heavily utilizes single-cell omics to map the complex cellular landscape of the brain, leading to numerous publications and scientific breakthroughs.
Why did Asia Pacific Grow Notably in the Market in 2024?
Asia Pacific is anticipated to expand at a rapid CAGR during 2025-2034 in the Single-Cell Omics market. The increasing government funding and support for genomics research and personalized medicine initiatives in countries like China, Japan, and India. The region is witnessing a rapid expansion of R&D infrastructure, growing interest from both local and international biotechnology firms, and a rising awareness of advanced healthcare technologies.
For instance,
- In March 2024, 10x Genomics introduced its next-generation architecture, GEM-X. The first products using this technology, the Chromium GEM-X Single Cell Gene Expression v4 and GEM-X Single Cell Immune Profiling v3 assays, offer enhanced performance, improved workflows, and greater cost-effectiveness for researchers.
Get the latest insights on life science industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership
US FDA: Approved Single-Cell Omics in 2024-2025
| US FDA | |
| CLIA-certified Labs | For diagnostic purposes within the scope of laboratory-developed tests (LDTs). |
| Companion Diagnostics (CDx) | For specific, targeted therapies. |
| Amtagvi (lifileucel) | For solid tumours. |
| Ryoncil (remestemcel-L) | For pediatric graft-versus-host disease. |
Segmental Insights
By Product Type Analysis
Which Product Type Led the Single-Cell Omics Market in 2024?
The single-cell genomics segment accounted for a dominant share of the market in 2024. The technological advancements and the need to understand cellular heterogeneity in complex diseases like cancer. North America currently dominates the market due to significant R&D investments and the presence of key players, with increased government funding and a focus on personalized medicine initiatives.
However, the single-cell metabolomics segment is predicted to expand at a lucrative CAGR. It's the ability to unveil cellular heterogeneity and identify crucial biomarkers. Technological advancements in sample analysis techniques, such as microfluidics and mass spectrometry, have made this field more accessible and reliable. It offers into the real-time functional state of individual cells is vital for the development of personalized medicine and advanced disease research
By Application Analysis
What Made the Oncology Segment Dominant in the Market in 2024?
The oncology segment held a major revenue share of the single-cell omics market in 2024. The technology has an unparalleled ability to decode the genetic and functional complexities of cancer cells. The insights gained into tumour heterogeneity, drug resistance mechanisms, and the tumour microenvironment are critical for biomarker discovery and the development of targeted, personalized therapies. Significant global research funding and direct clinical applications such as liquid biopsies and monitoring minimal residual disease.
By End use Analysis
What Made the Academic and Research Organizations Segment Dominant in the Market in 2024?
The academic and research organizations segment held a major revenue share of the single-cell omics market in 2024. The high capital expenditure on instruments, the extensive nature of academic research projects, focus on novel applications, and a more volatile commercial sector, academic institutions benefit from stable, multi-year funding cycles through government grants and non-profit organizations.
On the other hand, the pharmaceutical and biotechnology companies segment is estimated to expand rapidly in the predicted timeframe. The significant investment in research and development. These companies leverage single-cell omics to accelerate drug discovery, develop more effective precision medicines, and overcome drug resistance. The technology provides unparalleled insights into disease mechanisms at a cellular level, improving the identification and validation of therapeutic targets.
Browse More Insights of Towards Healthcare:
The global single-use mixers market was valued at USD 1.73 billion in 2025 and is projected to increase to USD 1.88 billion in 2026, reaching approximately USD 3.6 billion by 2034, expanding at a CAGR of 8.54% from 2024 to 2034.
The global single-use consumables market was valued at USD 2.99 billion in 2024 and is expected to grow to USD 3.49 billion in 2025, ultimately surpassing USD 13.83 billion by 2034 at a CAGR of 16.56% during the forecast period.
The global single-use duodenoscope market was valued at USD 160.5 million in 2024, rising to USD 206.14 million in 2025, and is projected to reach USD 1.98 billion by 2034, expanding rapidly at a CAGR of 28.44% between 2025 and 2034.
The global single-cell sequencing market was valued at USD 1.63 billion in 2024 and is forecast to grow to USD 1.88 billion in 2025, with expectations to exceed USD 6.65 billion by 2034, progressing at a CAGR of 15.05% over the forecast period.
The global single-use assemblies market was valued at USD 13.25 billion in 2024, increasing to USD 15.39 billion in 2025, and is anticipated to reach USD 58.44 billion by 2034, growing at a CAGR of 16.15% between 2025 and 2034.
The global single-cell biotherapeutics market is on a strong upward trajectory and is expected to generate significant revenue growth, potentially reaching several hundred million dollars between 2025 and 2034.
The global single-use downstream bioprocessing market was valued at USD 1.57 billion in 2024, increased to USD 1.79 billion in 2025, and is projected to reach USD 5.9 billion by 2034, registering a CAGR of 14.24% during the forecast period.
The global single-use sensors market was valued at USD 0.47 billion in 2024, rose to USD 0.54 billion in 2025, and is estimated to reach USD 1.86 billion by 2034, expanding at a CAGR of 15.04% from 2025 to 2034.
The global single-use bioreactors market was valued at USD 4.59 billion in 2024, increased to USD 5.38 billion in 2025, and is projected to reach USD 22.46 billion by 2034, growing at a CAGR of 17.21% between 2025 and 2034.
The global single-use pump market was valued at USD 451.81 million in 2023 and is expected to reach approximately USD 2.13 billion by 2034, registering a CAGR of 15.95% from 2024 to 2034.
What are the Revolutionary Developments in the Single-Cell Omics Market?
- In January 2024, Akoya Biosciences and Thermo Fisher Scientific are collaborating to combine their respective spatial multi-omics technologies to offer a more complete view of cell interactions within tissues
- In January 2024, Standard BioTools and SomaLogic merged to create a stronger entity in the multi-omics space, expanding their service and product portfolios
- In October 2024, BD announced the commercial launch of the BD OMICS-One XT WTA Assay, a new family of robotics-compatible reagent kits designed to automate single-cell discovery studies.
Single-Cell Omics Market Key Players List
- Standard BioTools Inc.
- Danaher Corporation
- Mission Bio
- CYTENA GmbH
- Bio-Rad Laboratories, Inc.
- 10x Genomics
- Illumina, Inc.
- BD
- ANGLE plc
- CELLENION
Segments Covered in this Report
By Product Type
- Single-Cell Genomics
- Single-Cell Metabolomics
- Single-Cell Transcriptomics
- Single-Cell Proteomics
By Application
- Oncology
- Immunology
- Cell Biology
- Neurology
By End-User
- Academic and Research Organizations
- Pharmaceutical & Biotechnology Companies
- Hospital and Diagnostic Laboratories
- Others
By Region
- North America
- U.S.
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Thailand
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Sweden
- Denmark
- Norway
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East and Africa (MEA)
- South Africa
- UAE
- Saudi Arabia
- Kuwait
Immediate Delivery Available | Buy This Premium Research @ https://www.towardshealthcare.com/checkout/5561
Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway.
Access the Dashboard: https://www.towardshealthcare.com/access-dashboard
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth.
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
Europe Region: +44 778 256 0738
North America Region: +1 8044 4193 44
APAC Region: +91 9356 9282 04
Web: https://www.towardshealthcare.com
Our Trusted Data Partners
Precedence Research | Statifacts | Towards Packaging | Towards Automotive | Towards Food and Beverages | Towards Chemical and Materials | Towards Consumer Goods | Towards Dental | Towards EV Solutions | Nova One Advisor | Healthcare Webwire | Packaging Webwire | Automotive Webwire | Nutraceuticals Func Foods | Onco Quant | Sustainability Quant | Specialty Chemicals Analytics
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium | Pinterest
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
